Spero Therapeutics (NASDAQ:SPRO) Stock Price Crosses Below Two Hundred Day Moving Average – Time to Sell?

Spero Therapeutics, Inc. (NASDAQ:SPRO) shares passed below its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $2.47 and traded as low as $2.20. Spero Therapeutics shares last traded at $2.21, with a volume of 433,658 shares traded.

Analyst Upgrades and Downgrades

SPRO has been the subject of a number of recent analyst reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Spero Therapeutics in a research note on Tuesday, April 21st. Wall Street Zen cut shares of Spero Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Saturday, May 16th. One research analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Reduce”.

Spero Therapeutics Trading Down 0.9%

The firm has a market cap of $127.38 million, a price-to-earnings ratio of 9.17 and a beta of 1.49. The company has a 50 day moving average of $2.58 and a 200 day moving average of $2.47.

Spero Therapeutics (NASDAQ:SPRO) last posted its earnings results on Wednesday, May 13th. The company reported ($0.13) earnings per share for the quarter, topping the consensus estimate of ($0.18) by $0.05. Spero Therapeutics had a return on equity of 35.58% and a net margin of 24.90%.The firm had revenue of $0.26 million for the quarter, compared to analyst estimates of $0.26 million.

Insider Activity

In related news, insider Esther Rajavelu sold 25,240 shares of the stock in a transaction that occurred on Monday, May 4th. The stock was sold at an average price of $2.51, for a total transaction of $63,352.40. Following the completion of the sale, the insider directly owned 986,851 shares of the company’s stock, valued at approximately $2,476,996.01. This represents a 2.49% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Corporate insiders own 2.90% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of SPRO. GSK plc acquired a new position in shares of Spero Therapeutics in the fourth quarter valued at approximately $21,414,000. Arrowstreet Capital Limited Partnership acquired a new stake in shares of Spero Therapeutics during the third quarter worth $283,000. OMERS ADMINISTRATION Corp bought a new stake in Spero Therapeutics in the 4th quarter valued at $306,000. Squarepoint Ops LLC acquired a new position in Spero Therapeutics in the 4th quarter worth $278,000. Finally, Shay Capital LLC acquired a new position in Spero Therapeutics in the 3rd quarter worth $120,000. Institutional investors own 25.60% of the company’s stock.

Spero Therapeutics Company Profile

Spero Therapeutics is a clinical?stage biopharmaceutical company focused on the discovery and development of novel therapies to address multidrug?resistant bacterial infections. Headquartered in Boston, Massachusetts, the company aims to advance a pipeline of oral and intravenous antibiotic candidates designed to treat serious infectious diseases that pose significant public health challenges.

The company’s lead candidate, tebipenem HBr, is an oral carbapenem antibiotic being developed for the treatment of complicated urinary tract infections caused by resistant Gram?negative pathogens.